Japan's drug firms on the move
A homespun elixir
With growth limited at home, Japan’s pharma industry is buying firms abroad
May 20th 2010 | TOKYO
Wednesday February 8th 2012
Advertisement
Most commented
- Tibetans and the Chinese state: No power to pacify
- Will the euro survive 2012 intact?
- Lexington: The classes drift apart
- Competition: Our forthcoming China blog
- Birtherism 2012: To the nation born
- Syria: Moscow rules
- Hong Kong and the mainland: Dogs and locusts
- Chinese college students: Making ting tong cool
- America in Afghanistan: Outta here
- Charlemagne: Angela the lawgiver
Over the past five days
Most recommended
- Pollution in China: Man-made and visible from space
- Facebook: A fistful of dollars
- Daily chart: Facebook by numbers
- China: The paradox of prosperity
- Riding India's railways: All aboard the Vivek Express
- Alcohol: Possibly the best travel tip ever
- JAS's cartoon: The week ahead
- Remembering Raoul Wallenberg: A necessary example of tolerance
- Pakistan's security state: Reading the Taliban
- Fernando Henrique Cardoso on Brazil's future: More personal security, less inequality
Over the past seven days
Advertisement
Products & events
Stay informed today and every day
Subscribe to The Economist's free e-mail newsletters and alerts.
Subscribe to The Economist's latest article postings on Twitter
See a selection of The Economist's articles, events, topical videos and debates on Facebook.
Classified ads
Readers' comments
Reader comments are listed below. Comments are currently closed and new comments are no longer being accepted.
Sort:
Ranbaxy is a good company, gave gr8 stock returns. Good for Daichi Sankyo and other Japanese firms, way to go!
Just a correction: the mandatory price cuts are not biannual (twice a year) as you wrote, but biennial (every two years).
I am not usually pedantic but this difference is rather important for pharma in Japan.
Pelle Stolt